Lorenz C. Hofbauer mainly investigates Internal medicine, Endocrinology, Osteoprotegerin, Osteoporosis and Bone remodeling. His study looks at the relationship between Internal medicine and fields such as Diabetes mellitus, as well as how they intersect with chemical problems. His Endocrinology research incorporates themes from Calcification, RANK Ligand and Osteoblast.
The concepts of his Osteoprotegerin study are interwoven with issues in Osteoclast, Cytokine, Bone resorption and RANKL. Lorenz C. Hofbauer studied RANKL and Bone disease that intersect with Bone marrow and Lesion. The study incorporates disciplines such as Vitamin D and neurology and Pharmacotherapy in addition to Osteoporosis.
Lorenz C. Hofbauer spends much of his time researching Internal medicine, Endocrinology, Cancer research, Bone remodeling and Osteoporosis. His Internal medicine study often links to related topics such as Oncology. Lorenz C. Hofbauer combines subjects such as Sclerostin, Receptor and Osteoblast with his study of Endocrinology.
The Cancer research study combines topics in areas such as Haematopoiesis, Immunology, Bone marrow, Breast cancer and Prostate cancer. His Bone remodeling study integrates concerns from other disciplines, such as Osteocalcin, Bone density and Cortical bone. His research in Osteoporosis intersects with topics in Vitamin D and neurology and Surgery.
His primary areas of investigation include Internal medicine, Endocrinology, Cancer research, Bone remodeling and Osteoporosis. His Internal medicine study combines topics from a wide range of disciplines, such as Sclerostin and Oncology. Lorenz C. Hofbauer interconnects Cortical bone, Wnt signaling pathway, DKK1 and Osteoblast in the investigation of issues within Endocrinology.
His study in Cancer research is interdisciplinary in nature, drawing from both Haematopoiesis, Receptor, Bone metastasis, Prostate cancer and Bone marrow. His work on Teriparatide is typically connected to Placebo as part of general Osteoporosis study, connecting several disciplines of science. His studies in RANKL integrate themes in fields like Osteoprotegerin and Adverse effect.
Internal medicine, Bone remodeling, Osteoporosis, Endocrinology and Cancer research are his primary areas of study. His Internal medicine research is multidisciplinary, incorporating elements of Sclerostin and Oncology. His Bone remodeling research incorporates themes from Glucose uptake, Physiology and Endocrine system.
His work in the fields of Denosumab, Teriparatide and Bone mineral overlaps with other areas such as Context and Likert scale. His Endocrinology research includes themes of DKK1 and Osteoblast. The Cancer research study combines topics in areas such as Statin, Apoptosis, Cancer cell, Receptor and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Osteoporosis: now and the future
Tilman D Rachner;Sundeep Khosla;Lorenz C Hofbauer.
The Lancet (2011)
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Lorenz C. Hofbauer;Michael Schoppet.
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Lorenz C. Hofbauer;Armin E. Heufelder.
Journal of Molecular Medicine (2001)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
F. Cosman;D. B. Crittenden;J. D. Adachi;N. Binkley.
The New England Journal of Medicine (2016)
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Jacques P. Brown;Richard L. Prince;Chad L Deal;Robert R. Recker.
Journal of Bone and Mineral Research (2009)
Osteoporosis in patients with diabetes mellitus.
Lorenz C Hofbauer;Lorenz C Hofbauer;Carolin C Brueck;Carolin C Brueck;Shiv K Singh;Harald Dobnig.
Journal of Bone and Mineral Research (2007)
Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease
Michael Schoppet;Alexander M. Sattler;Juergen R. Schaefer;Matthias Herzum.
The Journal of Clinical Endocrinology and Metabolism (2003)
Leptin reduces ovariectomy-induced bone loss in rats.
Bartolome Burguera;Lorenz C. Hofbauer;Thierry Thomas;Francesca Gori.
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
Volker Viereck;Günter Emons;Vanessa Lauck;Karl-Heinz Frosch.
Biochemical and Biophysical Research Communications (2002)
Osteoporosis treatment: recent developments and ongoing challenges
Sundeep Khosla;Lorenz C Hofbauer.
The Lancet Diabetes & Endocrinology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: